Lung cancer and immunotherapy: a real-life experience from second line and beyond.

This study assessed the efficacy of anti-PD-1/PD-L1 agents in real life when used in second line or beyond. Patients with advanced non-small-cell lung cancer progressing after standard chemotherapy and receiving immunotherapy in the second line or beyond were included. One hundred and ten patients were included with PD-L1 expression above 50%, between 1-49 and <1% in 38.6, 27.3 and 34.1% of patients, respectively. Checkpoint inhibitors were used as second, third and fourth line in 74.7, 21.8 and 3.5%, respectively. Partial response was observed in 25.6% of patients. Median progression-free survival was 4 months and median overall survival was 8.1 months. Immunotherapies are emerging as important tools in the oncologic field with good responses in real-life practice.